Q32 Bio Director Grayzel David S. Exercises $2.75 Stock Options, Boosting Insider Confidence
Q32 Bio’s insider activity: Director Grayzel David S. exercises new stock option, adding 16,363 shares at $2.75 each—signifying cautious, long‑term confidence in the biotech’s gene‑correction strategy.
4 minutes to read